IR@PKUHSC  > 北京大学第一临床医学院  > 核医学科
学科主题临床医学
Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging
Lu, Xia1,2,3; Yan, Ping1; Wang, Rong-fu1; Liu, Meng1; Yu, Ming-ming4; Zhang, Chun-li1
关键词Iodine-131 Peptide Arg-Arg-Leu (tRRL) Uptake ability Molecular tumor imaging
刊名CHINESE JOURNAL OF CANCER RESEARCH
2012-03-01
DOI10.1007/s11670-012-0052-8
24期:1页:52-59
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PHAGE DISPLAY ; ANGIOGENESIS ; THERAPY ; GROWTH ; CANCER ; SCINTIGRAPHY ; VASCULATURE ; METASTASIS ; DISEASES
英文摘要

To explore a tumor peptide imaging agent Arginine-Arginine-Leucine (Tyr-Cys-Gly-Gly-Arg-Arg-Leu-Gly-Gly-Cys, tripeptide RRL [tRRL]) that targeted to tumor cells and tumor-derived endothelial cells (TDECs) and primarily investigate the possible relationship between tRRL and vascular endothelial growth factor receptor 2 (VEGFR-2).

The tRRL sequence motif was identified as a tumor molecular marker specifically binding to TDECs. Tyrosine was conjugated to the amino terminal of RRL (Cys-Gly-Gly-Arg-Arg-Leu-Gly-Gly-Cys) for labeling with radionuclide iodine-131 (I-131-tRRL). The uptake ability and molecular binding of tRRL to tumor cells and angiogenic endothelium were studied using flow cytometry and radioactivity counter in vitro. Whether VEGFR-2 is the binging site of tRRL was investigated. Biodistribution and single-photon emission computed tomography (SPECT) imaging of I-131-tRRL were used to evaluate the effectiveness of this new imaging agent to visualize varied tumor xenografts in nude mice.

In vitro cellular uptake experiments revealed that tRRL could not only adhere to tumor angiogenic endothelial cells but also largely accumulate in malignant tumor cells. VEGFR-2, which is highly expressed on TDECs, was probably not the solely binding ligand for tRRL targeted to tumor angiogenic endothelium. I-131-tRRL mainly accumulated in tumors in vivo, not other organs at 24 h after injection. SPECT imaging with I-131-tRRL clearly visualized tumors in nude mice, especially at 24 h.

Radioiodinated tRRL offers a noninvasive nuclear imaging method for functional molecular imaging of tumors targeted to neovascularization, and may be a promising candidate for tumor radioimmunotherapeutic carrier.

语种英语
WOS记录号WOS:000300313500008
项目编号NSFC 30870729 ; 81071183/H1806 ; 30900374 ; 2006CB705705-1 ; 985-2-056 ; 200800011061
资助机构National Natural Science Foundation of China ; National "973" Basic Research Program of China ; National Education Ministry 985 Project of China ; Research Fund for the Doctoral Program of Higher Education of China
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63196
专题北京大学第一临床医学院_核医学科
北京大学口腔医学院_护理部
作者单位1.Peking Univ, Hosp 1, Dept Nucl Med, Beijing 100034, Peoples R China
2.Beijing Aerosp Gen Hosp, Radiol Ctr, Beijing 100076, Peoples R China
3.Beijing Normal Univ, Coll Chem, Minist Educ, Key Lab Radiopharmaceut, Beijing 100191, Peoples R China
4.Yangzhou Univ, Clin Med Coll, Dept Nucl Med, Yangzhou 225000, Peoples R China
推荐引用方式
GB/T 7714
Lu, Xia,Yan, Ping,Wang, Rong-fu,et al. Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging[J]. CHINESE JOURNAL OF CANCER RESEARCH,2012,24(1):52-59.
APA Lu, Xia,Yan, Ping,Wang, Rong-fu,Liu, Meng,Yu, Ming-ming,&Zhang, Chun-li.(2012).Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging.CHINESE JOURNAL OF CANCER RESEARCH,24(1),52-59.
MLA Lu, Xia,et al."Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging".CHINESE JOURNAL OF CANCER RESEARCH 24.1(2012):52-59.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lu, Xia]的文章
[Yan, Ping]的文章
[Wang, Rong-fu]的文章
百度学术
百度学术中相似的文章
[Lu, Xia]的文章
[Yan, Ping]的文章
[Wang, Rong-fu]的文章
必应学术
必应学术中相似的文章
[Lu, Xia]的文章
[Yan, Ping]的文章
[Wang, Rong-fu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。